---

The Floppy Infant — A Comprehensive Pediatric Master Guide

---

1. Definition and Core Concepts

• Weakness (decreased muscle power/force generation during voluntary contraction)
• Ligamentous laxity (increased joint range of motion without true neurological hypotonia)

Clinical pearl: Tone ≠ Strength. A hypotonic infant may have near-normal strength when aroused (e.g., during a blood draw), pointing toward a central rather than peripheral cause.

---

2. Pathophysiology: Central vs. Peripheral Hypotonia

---

3. Etiology: Causes of the Floppy Infant Syndrome

CENTRAL CAUSES (Upper Motor Neuron / Brain)

• Most common cause of neonatal hypotonia in the term infant
• Perinatal asphyxia → glutamate excitotoxicity → neuronal death
• Features: encephalopathy, seizures, abnormal tone, feeding difficulty
• Graded by Sarnat staging (mild/moderate/severe)

• Prader-Willi Syndrome (PWS): Chromosome 15q11-13 deletion (paternal) or maternal UPD; presents as the most classic "central floppy infant" — profound hypotonia, feeding difficulty requiring NG tube, later hyperphagia and obesity; cryptorchidism and almond-shaped eyes are clues
• Trisomy 21 (Down Syndrome): Hypotonia plus characteristic dysmorphic features; atlantoaxial instability requires screening
• Trisomies 13 and 18; various microdeletion syndromes

• Lissencephaly, pachygyria, polymicrogyria, agenesis of corpus callosum
• Cerebellar hypoplasia/Dandy-Walker spectrum
• MRI brain essential for diagnosis

• Hypoglycemia, hypocalcemia, hypomagnesemia, hyperammonemia → all acutely reversible causes that must be excluded first
• Pompe disease (GSD type II / Acid Maltase Deficiency): Glycogen accumulation in muscle and anterior horn cells → profound weakness, cardiomegaly, hepatomegaly, macroglossia; CK elevated; treatment: alglucosidase alfa (ERT)
• Congenital Disorders of Glycosylation (CDG type Ia): Phosphomannomutase deficiency → hypotonia + hyporeflexia + cerebellar hypoplasia + inverted nipples + abnormal fat distribution; confirm with transferrin isoelectric focusing
• Mitochondrial disorders, organic acidemias, urea cycle defects

• Zellweger syndrome: Hypotonia + hepatomegaly + characteristic facies + absence of peroxisomes; elevated very-long-chain fatty acids (VLCFA)

---

PERIPHERAL CAUSES (Lower Motor Neuron)

• Most important peripheral cause in a neonate/infant
• Loss of SMN1 gene (chromosome 5q) → anterior horn cell degeneration
• SMA Type 1 (Werdnig-Hoffmann disease): Onset < 6 months; never sits; paradoxical breathing (chest wall collapse with abdominal breathing); tongue fasciculations; absent DTRs; preserved alertness and eye movements; median survival < 2 years without treatment historically
• SMA Type 2: Onset 6–18 months; achieves sitting, never stands
• SMA Type 3 (Kugelberg-Welander): Onset after 18 months; ambulatory

• Birth trauma (especially breech delivery, forceps delivery)
• Cervical spinal cord injury → generalized hypotonia below level of lesion
• May present with bladder distention, absent DTRs below level, associated HIE

• Congenital hypomyelinating neuropathy / Dejerine-Sottas disease: Absent DTRs, NCS shows severely reduced conduction velocities
• Hereditary motor and sensory neuropathies (HMSN)

• Neonatal myasthenia gravis: Transient; maternal acetylcholine receptor antibodies cross placenta; improves within weeks; neostigmine test
• Congenital myasthenic syndromes: Permanent; due to mutations in NMJ proteins; edrophonium/neostigmine trial, repetitive nerve stimulation shows decrement
• Infant botulism: Clostridium botulinum spores (honey! soil) ingested → toxin blocks presynaptic ACh release; descending flaccid paralysis; constipation is often the first symptom; cranial nerve involvement (weak cry, poor suck, ptosis, dilated pupils); clear sensorium; EMG shows incremental response on high-frequency stimulation (SFEMG most sensitive); treatment = BabyBIG (human botulism immune globulin) — reduces hospitalization by 3–4 weeks

• Congenital myopathies (structural myopathies):
  • Central core disease (RYR1 mutation): Hypotonia at birth, non-progressive; cores on Gomori trichrome; associated with malignant hyperthermia risk
  • Nemaline (rod-body) myopathy: Rod-shaped inclusions on Gomori; can be fatal respiratory neonatal form
  • Centronuclear/myotubular myopathy (MTM1 gene): Severe neonatal form in males (X-linked); central nuclei in myofibers; poor prognosis in X-linked form
  • Fiber-type disproportion: Small type I fibers
• Congenital Muscular Dystrophies (CMD):
  • Merosin-deficient CMD: Absent laminin-α2 on muscle biopsy; white matter changes on MRI; CMD confirmed by genetic testing
  • Ullrich CMD, rigid spine syndrome:
• Myotonic Dystrophy type 1 (congenital form): Maternal CTG repeat expansion (DMPK gene); severe neonatal hypotonia, respiratory failure, bilateral facial weakness, talipes; mother often mildly symptomatic with grip myotonia → examine the mother!
• Infantile Pompe disease (also listed above as metabolic/combined)

---

4. Clinical Features and Physical Examination

Classic "Floppy" Postures on Inspection

• Supine resting posture: Legs in external rotation lying flat (frog-leg posture); arms extended by sides — contrast with the normal flexed frog posture of a healthy term infant
• Ventral suspension (prone suspension): Normal infant maintains head level with body and limbs semi-flexed; hypotonic infant drapes like an inverted "U" over the examiner's hand (rag-doll posture)
• Vertical suspension: Normal infant remains suspended with shoulder girdle strength; hypotonic infant slips through hands
• Pull-to-sit (traction response): Normal response includes elbow/knee/ankle flexion with minimal head lag (present normally after 33 weeks post-conceptional age); hypotonic infant shows profound head lag (see image above)

Key Clinical Signs to Differentiate Central from Peripheral

---

5. Diagnostic Approach

Step 1: Immediate Stabilization and Rule Out Reversible/Life-Threatening Causes

• Airway — hypotonia causes loss of airway control; may need intubation
• Breathing — paradoxical respiration suggests SMA or diaphragmatic weakness
• Circulation — sepsis is a reversible cause of hypotonia

Step 2: History (ESSENTIAL — Narrows Differential Before Any Test)

Step 3: First-Line Investigations (All Hypotonic Infants)

Step 4: Targeted Second-Line Investigations Based on Clinical Localization

• MRI brain ± spine — structural malformation, HIE, leukodystrophy, Dandy-Walker
• EEG — subclinical seizures
• TORCH serology
• Chromosomal microarray / exome sequencing
• Urine/serum for CDG (transferrin isoelectric focusing)
• Very-long-chain fatty acids (Zellweger, peroxisomal)
• Plasma amino acids, urine organic acids, acylcarnitine profile

• Nerve conduction studies (NCS) + EMG
  • Decreased conduction velocity → neuropathy
  • Absent sensory potentials → neuropathy
  • Fibrillations + positive sharp waves → denervation (SMA)
  • Decremental response on repetitive stimulation → NMJ (myasthenia)
  • Incremental response at high frequency → botulism
• CK: Markedly elevated in congenital muscular dystrophies
• SMN1 gene deletion analysis — now first-line for suspected SMA (detects 95–98% of SMA)
• Anti-AChR antibodies — neonatal myasthenia
• Stool culture for C. botulinum and toxin — infant botulism
• Muscle biopsy (histochemistry, electron microscopy) — congenital myopathy diagnosis
• Skin/peripheral nerve biopsy — infantile neuroaxonal dystrophy
• Genetic panel / whole exome sequencing — where molecular diagnosis needed

Hammersmith Infant Neurological Examination (HINE): The strongest validated tool for quantifying hypotonia severity in infants 2 months to 2 years (Hidalgo Robles et al., 2024, PMID 38391868). Use it for serial assessments.

---

6. Red Flags — Do Not Miss

---

7. Management

A. Acute / Emergency Management

1. Stabilize the airway — anticipate need for intubation in any infant with respiratory distress; diaphragm weakness means rapid deterioration
2. Correct reversible causes immediately:
   • Hypoglycemia → IV dextrose
   • Hypocalcemia → IV calcium gluconate
   • Hypothyroidism → levothyroxine
   • Sepsis → broad-spectrum antibiotics
3. Therapeutic hypothermia — if HIE is the cause, initiate within 6 hours of birth (33–34°C for 72 hours) per standard AAP/WHO protocols (must meet Sarnat grade II–III criteria)
4. BabyBIG (Human Botulism Immune Globulin) — administer IV as early as possible in infant botulism; reduces hospitalization by average 3.6 weeks; FDA-approved; do NOT give aminoglycosides (potentiate NMJ blockade)

B. Disease-Specific Pharmacological Treatment

C. Non-Pharmacological Management (Critical in ALL floppy infants)

• Physiotherapy — prevent contractures, promote motor development; stretching and positioning from early infancy
• Occupational therapy — activities of daily living, adaptive equipment
• Speech and feeding therapy — coordinate suck-swallow-breathe; assess for aspiration risk
• Nasogastric tube (NG) or gastrostomy (PEG/G-tube) — if feeding inadequate or aspiration risk high
• Non-invasive ventilation (NIV/BiPAP) — for chronic respiratory insufficiency (SMA type 1, CMD)
• Orthopedic management — scoliosis surveillance and bracing/surgery; joint contracture management
• Aggressive respiratory infection management + annual influenza vaccination
• Cardiac surveillance — echo in Pompe, congenital myotonic dystrophy, Emery-Dreifuss
• GERD management — common in hypotonic infants

---

8. Differential Diagnosis Summary (Practical Framework)

FLOPPY INFANT
│
├── ALERT, NORMAL REFLEXES, POOR POWER
│   └── PERIPHERAL CAUSE
│       ├── Absent DTRs + fasciculations → SMA (SMN1 analysis URGENT)
│       ├── Absent DTRs, no fasciculations, NCS abnormal → Neuropathy
│       ├── Ptosis + fatigability, decrement on RNS → Myasthenia
│       ├── Constipation + descending weakness + afebrile → Botulism
│       └── Elevated CK + muscle biopsy changes → CMD / Congenital myopathy
│
└── ENCEPHALOPATHIC, NORMAL/BRISK REFLEXES, RELATIVELY NORMAL POWER
    └── CENTRAL CAUSE
        ├── Birth asphyxia + seizures → HIE
        ├── Dysmorphic + chromosomal → Trisomy 21/13/18, PWS, microdeletion
        ├── Macroglossia + cardiomegaly → Pompe
        ├── Constipation + later hyperphagia + genital hypoplasia → PWS
        ├── MRI white matter changes → Leukodystrophy, CDG, lysosomal
        └── Normal MRI + normal chromosomes → Benign congenital hypotonia

---

9. Complications and Prevention

---

10. Prognosis and Long-Term Outcomes

---

11. Long-Term Follow-Up

• Serial neurological assessments; respiratory function (FVC); motor milestone tracking
• Repeat nusinersen injections (loading: 4 doses over 63 days; maintenance: every 4 months)
• Scoliosis, nutritional, and swallowing surveillance

• ERT infusions every 2 weeks lifelong
• Cardiac echo (infantile form has cardiomyopathy)
• Respiratory function; GI; audiology

• Echocardiogram at birth (AVSD, VSD)
• Thyroid function annually
• Atlantoaxial instability screening at 3–5 years
• Audiology, ophthalmology annually
• Sleep study for OSA
• Leukemia surveillance

• Growth hormone therapy from infancy (FDA-approved)
• Endocrinology (hypogonadism, diabetes risk)
• Behavioral/psychiatric support
• Obesity prevention (strict dietary environment)
• GnRH analogs for puberty management

• Cardiac MRI/echo annually
• Pulmonary function + sleep study
• Orthopedic: scoliosis, contractures
• Nutritional assessment

---

12. Patient-Centered and Family-Centered Care

Psychological Impact on Families

• Break the news honestly and compassionately — use clear, non-medical language; involve both parents and key family members
• Avoid false reassurance — but maintain hope around disease-modifying treatments (especially SMA gene therapy)
• Acknowledge grief — anticipatory grief for a future the family imagined; normalize this response
• Provide written information and direct to reputable disease-specific organizations (Cure SMA, NORD, Prader-Willi Syndrome Association)

Multidisciplinary Team (MDT) — Essential

• Pediatric neurologist
• Pulmonologist / respiratory therapist
• Gastroenterologist / dietitian
• Physiotherapist (from day 1)
• Occupational therapist
• Speech and language therapist / feeding specialist
• Cardiologist (selected diagnoses)
• Orthopedic surgeon (scoliosis, contractures)
• Geneticist (for family counseling, recurrence risk)
• Palliative care team (when prognosis is guarded)
• Social worker and psychologist

Ethical Considerations

• Informed consent for genetic testing — implications for siblings and parents (carrier status)
• Newborn screening for SMA — now on the US Recommended Uniform Screening Panel (RUSP); enables pre-symptomatic treatment with dramatically superior outcomes; but raises questions about parental anxiety with early disclosure
• Goals of care discussions — particularly in SMA type 1 and severe CMD; ventilatory support decisions should be made collaboratively with family, guided by the child's best interests
• Transition to adult care — plan early for adolescents with chronic neuromuscular conditions

---

13. Clinical Reasoning Summary

1. Stabilize first — airway, breathing, circulation, glucose, calcium
2. Examine — is the baby alert with absent reflexes (peripheral) or encephalopathic with normal reflexes (central)?
3. History focus — maternal, family, delivery, exposures (honey!)
4. First-line labs — rule out reversible: glucose, calcium, TFTs, sepsis screen, CK, ammonia, lactate
5. Central → MRI brain; Peripheral → NCS/EMG → targeted genetic testing
6. SMA is the most dangerous peripheral cause you must not miss — send SMN1 deletion analysis early; time to treatment is critical
7. Infant botulism must be recognized clinically — stool test takes days; give BabyBIG on clinical suspicion if descending paralysis + constipation + afebrile + clear sensorium
8. Pompe disease must be recognized early — cardiomegaly + macroglossia + weakness = send acid alpha-glucosidase before the heart fails

---

Key References

• Bradley and Daroff's Neurology in Clinical Practice — Chapter 30: The Floppy Infant
• Adams and Victor's Principles of Neurology, 12th ed. — Chapter 37: Flaccid Paralyses and the Floppy Infant Syndrome (Table 37-7)
• Harrison's Principles of Internal Medicine 22E (2025) — Lower Motor Neuron Disorders, SMA
• Rosen's Emergency Medicine — Infant Botulism (Chapter 169)
• Hidalgo Robles Á et al. "Identifying and Evaluating Young Children with Developmental Central Hypotonia." Healthcare (Basel) 2024. PMID 38391868 — Validates HINE as the strongest assessment tool for central hypotonia
• Francisco R et al. "Neonatal tone management." Semin Fetal Neonatal Med 2024. PMID 39537451 — MDT approach, importance of serial examinations and early intervention
• AAP Newborn Screening — SMA added to RUSP 2018
• Stonybrook/Pediatrics in Review 2009: "The Floppy Infant: Evaluation of Hypotonia" — systematic approach framework still widely used

---